Poly Medicure Intrinsic Value
Poly Medicure intrinsic value. Poly Medicure (POLYMED) median intrinsic value is ₹655.20 from 10 valuation models (range ₹486–₹1235), vs current price ₹1619.60 — -59.5% downside (Trading Above Calculated Value), margin of safety -100.0%. Read POLYMED dividend growth for the complete payout history and dividend yield track record.
POLYMED Valuation Methods Summary — DCF, Graham Number & P/E
Poly Medicure intrinsic value across 10 models vs current price ₹1619.60 — upside/downside and value range per method. For current market price and key ratios, visit Poly Medicure screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹575.52 | ₹460.42 - ₹690.62 | -64.5% | EPS: ₹26.16, Sector P/E: 22x |
| Book Value Method | asset | ₹1234.90 | ₹1111.41 - ₹1358.39 | -23.8% | Book Value/Share: ₹617.45, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹869.02 | ₹782.12 - ₹955.92 | -46.3% | Revenue/Share: ₹434.51, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1019.61 | ₹917.65 - ₹1121.57 | -37.0% | EBITDA: ₹520.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹655.20 | ₹524.16 - ₹786.24 | -59.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹485.88 | ₹437.29 - ₹534.47 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹485.88 | ₹437.29 - ₹534.47 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹809.80 | ₹728.82 - ₹890.78 | -50.0% | ROE: 8.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹602.85 | ₹542.57 - ₹663.14 | -62.8% | EPS: ₹26.16, BVPS: ₹617.45 |
| Dividend Yield Method | dividend | ₹485.88 | ₹437.29 - ₹534.47 | -70.0% | DPS: ₹3.50, Target Yield: 2.5% |
POLYMED Intrinsic Value vs Market Price — All Valuation Models
Poly Medicure fair value range ₹486–₹1235 vs current market price ₹1619.60 across 10 valuation models. Compare with POLYMED stock valuation models to assess whether the stock is under or overvalued.
POLYMED Intrinsic Value Analysis — Undervalued or Overvalued?
Poly Medicure median intrinsic value ₹655.20, current price ₹1619.60 — Trading Above Calculated Value by 59.5%, margin of safety -100.0%.
What is the intrinsic value of POLYMED?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Poly Medicure (POLYMED) is ₹655.20 (median value). With the current market price of ₹1619.60, this represents a -59.5% variance from our estimated fair value.
The valuation range spans from ₹485.88 to ₹1234.90, indicating ₹485.88 - ₹1234.90.
Is POLYMED undervalued or overvalued?
Based on our multi-method analysis, Poly Medicure (POLYMED) appears to be trading above calculated value by approximately 59.5%.
POLYMED Financial Health — Key Ratios vs Industry Benchmarks
Poly Medicure financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 10.01 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 8.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
POLYMED Cash Flow Quality — Operating & Free Cash Flow
Poly Medicure operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹246 Cr | ₹134 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹233 Cr | ₹-361 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹266 Cr | ₹146 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹191 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹124 Cr | ₹82 Cr | Positive Free Cash Flow | 8/10 |